You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure
Contributor:
Korkmaz‐Icöz, Sevil;
Radovits, Tamás;
Szabó, Gábor
Published:
Wiley, 2018
Published in:
British Journal of Pharmacology, 175 (2018) 2, Seite 223-231
Language:
English
DOI:
10.1111/bph.13749
ISSN:
0007-1188;
1476-5381
Origination:
Footnote:
Description:
<jats:sec><jats:label /><jats:p>Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′‐GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP‐dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure.</jats:p></jats:sec><jats:sec><jats:title>Linked Articles</jats:title><jats:p>This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc">http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc</jats:ext-link></jats:p></jats:sec>